Sign in
Taking people in United KingdomNo phase

Tests hesperidin supplement for fatigue and mood in multiple sclerosis

Tests a daily citrus-derived supplement against placebo in adults with multiple sclerosis.

Key facts

Who runs it
Swansea University
Where
Swansea, United KingdomSee the site
Trial code
Registry title
Hesperidin RCT in MS
Status
Recruiting
People taking part
60 people, planned
Started
7 Jan 2026
Expected to end
18 Jan 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Hesperidin
  • Placebo
Record updated
5 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with multiple sclerosis. It tests whether hesperidin supplement or a placebo for 12 weeks helps fatigue, mood and thinking.

Age
18 years or older
Sex
All sexes can join.
Disease stage
A diagnosis of multiple sclerosis. No stage or severity is stated.

Main reasons for not taking part

  • Known food allergies or intolerances
  • Significant stomach or gut (gastrointestinal) problems
  • Under 18 years of age

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Diagnosis of Multiple Sclerosis, Aged 18 years or older

Who cannot take part

  • Known food allergies, intolerances, or significant gastrointestinal (GI) problems, Participants under the age of 18 years

Where in United Kingdom

  • FHMLS, Nutrition LabSwansea, United KingdomContact: Hayley A Young, PHDTaking people

About the trial

What the trial wants to find out

This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress.

Read full original descriptionShow less

Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.

The 2 groups in the trial

  • HesperidinExisting treatment, for comparison

    Participants receiving Hesperidin capsules for 12 weeks.

  • Placebo ComparatorPlacebo, for comparison

    Participants receiving matching placebo capsules for 12 weeks.

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Placebo-Controlled Trial of Hesperidin for Fatigue,Mood, and Cognitive Function in Multiple Sclerosis
Plain-language title
Tests hesperidin supplement for fatigue and mood in multiple sclerosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 March 2026